GF Fund Management’s Stoke Therapeutics STOK Stock Holding History

GF Fund Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.7K	Sell	1,212 -71	-6%	-$2.28K	﹤0.01%	416
2026 Q1	$41.8K	Buy	1,283 +162	+14%	+$5.31K	﹤0.01%	419
2025 Q4	$35.6K	Sell	1,121 -58	-5%	-$1.74K	﹤0.01%	441
2025 Q3	$27.7K	Sell	1,179 -176	-13%	-$3.02K	﹤0.01%	450
2025 Q2	$15.4K	Hold	1,355	–	–	﹤0.01%	525
2025 Q1	$9.01K	Buy	1,355 +243	+22%	+$2.27K	﹤0.01%	580
2024 Q4	$12.3K	Buy	+1,112	New	+$13.7K	﹤0.01%	520

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GF Fund Management's STOK Position: Q2 2026 in Review

GF Fund Management reduced its Stoke Therapeutics (STOK) stake by 5.5% in Q2 2026, selling an estimated $2.28K and leaving 1,212 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #416.

GF Fund Management first reported a position in STOK in Q4 2024 and has held it in 7 quarters since. The position peaked at $41.8K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

GF Fund Management held 1,212 shares of Stoke Therapeutics worth $39.7K as of Q2 2026.
GF Fund Management sold 71 Stoke Therapeutics shares in Q2 2026, an estimated $2.28K.
Stoke Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #416 holding.
GF Fund Management first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Stoke Therapeutics position peaked at $41.8K in Q1 2026.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.